Relief Financial Statements From 2010 to 2024
| RLFTF Stock | USD 5.36 0.22 3.94% |
Check Relief Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Relief Therapeutics' main balance sheet or income statement drivers, such as , as well as many indicators such as . Relief financial statements analysis is a perfect complement when working with Relief Therapeutics Valuation or Volatility modules.
Relief |
Relief Therapeutics Holding OTC Stock Return On Equity Analysis
Relief Therapeutics' Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current Relief Therapeutics Return On Equity | -0.33 |
Most of Relief Therapeutics' fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Relief Therapeutics Holding is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
| Competition |
Based on the latest financial disclosure, Relief Therapeutics Holding has a Return On Equity of -0.3257. This is 98.64% lower than that of the Healthcare sector and 99.11% lower than that of the Biotechnology industry. The return on equity for all United States stocks is 5.06% higher than that of the company.
Relief Therapeutics Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Relief Therapeutics's current stock value. Our valuation model uses many indicators to compare Relief Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Relief Therapeutics competition to find correlations between indicators driving Relief Therapeutics's intrinsic value. More Info.Relief Therapeutics Holding is currently regarded as top stock in return on equity category among its peers. It also is currently regarded as top stock in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Relief Therapeutics' earnings, one of the primary drivers of an investment's value.About Relief Therapeutics Financial Statements
Relief Therapeutics stakeholders use historical fundamental indicators, such as Relief Therapeutics' revenue or net income, to determine how well the company is positioned to perform in the future. Although Relief Therapeutics investors may analyze each financial statement separately, they are all interrelated. For example, changes in Relief Therapeutics' assets and liabilities are reflected in the revenues and expenses on Relief Therapeutics' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Relief Therapeutics Holding. Please read more on our technical analysis and fundamental analysis pages.
Relief Therapeutics Holding AG, a biopharmaceutical company, provides patients with therapeutic relief from serious diseases with high unmet medical need in Switzerland, rest of Europe, North America, and internationally. The company was founded in 2013 and is based in Geneva, Switzerland. Mondobiotech Holding is traded on OTC Exchange in the United States.
Currently Active Assets on Macroaxis
Other Information on Investing in Relief OTC Stock
Relief Therapeutics financial ratios help investors to determine whether Relief OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Relief with respect to the benefits of owning Relief Therapeutics security.